This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals.View NVO key stats

Novo Nordisk A/S - NVO - EQUITY

Reviewed By: TheStreet Ratings on March 26, 2015.

Report Summary: TheStreet Ratings team rates Novo Nordisk A/S as a
Buy with a ratings score of A-.

Report Snippet: We rate Novo Nordisk A/S (NVO) a Buy.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.